» Articles » PMID: 12479272

The Biological Sequelae of Stromal Cell-derived Factor-1alpha in Multiple Myeloma

Overview
Journal Mol Cancer Ther
Date 2002 Dec 14
PMID 12479272
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Stromal cell-derived factor (SDF)-1alpha mediates migration of normal hematopoietic stem cells, but its role in hematological malignancies is undefined. In this study, we detected SDF-1alpha in bone marrow (BM) plasma from 10 patients with MM (multiple myeloma; 2.6 +/- 1.5 ng/ml) and BM stromal cell culture supernatants from 5 patients with MM (0.6 +/- 0.2 ng/ml). We show that SDF-1alpha promotes proliferation, induces migration, and protects against dexamethasone-induced apoptosis in MM cells, but these effects are only modest. In MM cell lines and patient MM cells, SDF-1alpha induces phosphorylation of p42/44 mitogen-activated protein kinase, as well as Akt and its downstream target Bad, and also activates nuclear factor-kappaB. In the BM milieu, SDF-1alpha up-regulates secretion of interleukin 6 and vascular endothelial growth factor in BM stromal cells, which promote tumor cell growth, survival, and migration. These data demonstrate that SDF-1alpha promotes growth, migration and drug resistance of MM cells in the BM microenvironment, but these effects are only modest, SDF-1alpha therefore does not represent a target for novel therapeutics in this disease.

Citing Articles

Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment.

Lu K, Wang W, Liu Y, Xie C, Liu J, Xing L Front Oncol. 2024; 14:1413494.

PMID: 39087026 PMC: 11288838. DOI: 10.3389/fonc.2024.1413494.


Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone.

Tachita T, Ri M, Aoki S, Asano A, Kanamori T, Totani H Cancer Med. 2024; 13(14):e70019.

PMID: 39031503 PMC: 11259000. DOI: 10.1002/cam4.70019.


Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes.

Binder M, Szalat R, Talluri S, Fulciniti M, Avet-Loiseau H, Parmigiani G Nat Commun. 2024; 15(1):4139.

PMID: 38755155 PMC: 11098817. DOI: 10.1038/s41467-024-47793-5.


Circulating biosignatures in multiple myeloma and their role in multidrug resistance.

Krishnan S, Bebawy M Mol Cancer. 2023; 22(1):79.

PMID: 37120508 PMC: 10148481. DOI: 10.1186/s12943-022-01683-w.


Past, Present, and a Glance into the Future of Multiple Myeloma Treatment.

Elbezanti W, Challagundla K, Jonnalagadda S, Budak-Alpdogan T, Pandey M Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986514 PMC: 10056051. DOI: 10.3390/ph16030415.